Is hyperuricemia an independent prognostic factor for IgA nephropathy: a systematic review and meta-analysis of observational cohort studies

• Published in: Renal failure Vol. 44; no. 1; pp. 70 - 80
• Main Authors: Zhang, Kang, Tang, Long, Jiang, Shang-shang, Wang, Yue-fen, Meng, Yuan, Wang, Meng-di, Cui, Fang-qiang, Cai, Zhen, Zhao, Wen-jing
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01.12.2022; Taylor & Francis Ltd; Taylor & Francis Group
• Subjects: Clinical trials; Cohort analysis; Cohort Studies; Creatinine; End-stage renal disease; Glomerulonephritis, IGA - blood; Glomerulonephritis, IGA - physiopathology; Humans; Hyperuricemia; Hyperuricemia - blood; IgA nephropathy; Immunoglobulin A; Immunoglobulin A nephropathy; Kidney diseases; Meta-analysis; Observational studies; Observational Studies as Topic; Prognosis; Renal failure; Review; Risk Factors; Sensitivity analysis; serum uric acid; State-of-the-Art Review; Systematic review; Uric acid; Uric Acid - blood; hyperuricemia; Immunoglobulin A nephropathy; serum uric acid; prognosis
• ISSN: 0886-022X; 1525-6049
• DOI: 10.1080/0886022X.2021.2019589

Hyperuricemia has been reported to be correlated with IgA nephropathy (IgAN). However, whether hyperuricemia or elevated serum uric acid (SUA) is an independent prognostic factor of IgAN remains unknown. Therefore, this systematic review and meta-analysis evaluated the prognostic value of hyperuricemia and elevated SUA in IgAN. Databases including PubMed, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), and Open Gray were reviewed systematically. The kidney failure events of IgAN were defined as a doubling of serum creatinine, halving of eGFR, end-stage renal disease (ESRD), or death. The risk ratio (RR) between hyperuricemia and IgAN-caused kidney failure was evaluated before and after adjustment for relevant covariates. The RR between elevated SUA and IgAN-caused kidney failure was evaluated after adjustment for relevant covariates. A total of 11 548 patients from 14 studies were included in this meta-analysis. Hyperuricemia was found to be an independent prognostic factor of IgAN (unadjusted RR = 2.79, 95% CI = 1.93-4.03, p for heterogeneity <0.00001, I 2  = 91%; adjusted RR = 2.12, 95% CI = 1.64-2.73, p for heterogeneity = 0.86, I 2 = 0%). Subgroup and sensitivity analyses confirmed the stability of these results. Similarly, elevated SUA was positively correlated with kidney failure events of IgAN (adjusted RR = 1.25, 95% CI = 1.19-1.31, p for heterogeneity = 0.6, I 2 = 0%). Our meta-analysis showed that hyperuricemia and elevated SUA were both independently associated with an increased incidence of kidney failure events in IgAN patients.